Profile: OSI Pharmaceuticals, Inc. produces and markets quality & novel pharmaceutical products that improve the quality of life for patients with cancer, eye diseases and diabetes. We market Tarceva® and Novantrone®. Our product Tarceva® is a small molecule human epidermal growth factor type 1/epidermal growth factor receptor which is currently marketed for the treatment of non-small cell lung cancer and pancreatic cancer. Our product Novantrone® is an anthracenedione used as an intravenous chemotherapy agent. This product in combination with other approved drugs is approved by the FDA for the treatment of acute non-lymphocytic leukemia (ANLL) in adults, which includes myelogenous, promyelocytic, monocytic & erythroid acute leukemias.